Grifols (NASDAQ:GRFS) Rating Lowered to “Hold” at Wall Street Zen

Grifols (NASDAQ:GRFS) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday.

Several other research analysts have also issued reports on GRFS. JPMorgan Chase & Co. cut their price target on Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a report on Monday, December 8th. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a report on Thursday, January 22nd. Finally, Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research report on Friday, February 6th. Four research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $10.00.

Grifols Stock Performance

Shares of NASDAQ GRFS opened at $8.76 on Friday. The firm’s 50-day moving average price is $9.18 and its 200-day moving average price is $9.27. The company has a current ratio of 2.51, a quick ratio of 0.88 and a debt-to-equity ratio of 1.20. Grifols has a 1-year low of $6.19 and a 1-year high of $11.14.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Brandes Investment Partners LP grew its position in Grifols by 8.9% in the 2nd quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock worth $253,441,000 after purchasing an additional 2,294,113 shares in the last quarter. Vinva Investment Management Ltd bought a new position in shares of Grifols during the 2nd quarter worth approximately $256,000. New York State Common Retirement Fund boosted its stake in shares of Grifols by 5.6% in the 3rd quarter. New York State Common Retirement Fund now owns 2,589,406 shares of the biotechnology company’s stock worth $25,790,000 after buying an additional 136,678 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Grifols by 31.8% in the third quarter. JPMorgan Chase & Co. now owns 2,488,294 shares of the biotechnology company’s stock valued at $24,783,000 after acquiring an additional 600,118 shares in the last quarter. Finally, AdvisorShares Investments LLC bought a new position in shares of Grifols in the third quarter valued at approximately $1,012,000.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.